Century Therapeutics
Main focus: Next-generation cell therapies for the treatment of cancer
Company stage: Pre-clinical
Diseases (gene editing): Cancer
Genome editing tool: CRISPR-MAD7
Funding stage: Public (NASDAQ:IPSC)
Location: Philadelphia, PA, USA
Website: https://www.centurytx.com/
Pipeline: https://www.centurytx.com/pipeline
Gene-editing partnerships: Inscripta, Bristol Myers Squibb
Century Therapeutics is developing next-generation cell-based therapies to treat haematological and solid tumours. The company uses its iPSC platform to generate allogeneic, iPSC-derived natural killer (NK) and T cell products. The company uses the CRISPR-MAD7 system to introduce multiple knock-outs to its cellular products, in order to avoid host-versus-graft reactions and increase persistence and durability.